Skip to content

DeepkinetiX

2 viewers · 30d

Total raised

$1.0M

1 filing since 2025 · latest Options filed

Cumulative raised
LAST ROUND
Options · $1.0M
ROUNDS
1
INVESTORS
1
FOUNDED
2024
HQ
Cambridge, MA
SECTOR
Biotech
EMPLOYEES
N/A
30D VIEWERS
2

AI overview

Updated

DeepkinetiX Inc. is a pioneering company dedicated to revolutionizing the drug development landscape through the innovative application of artificial intelligence and computational modeling techniques. By employing advanced technologies, they strive to optimize pharmacokinetic and pharmacodynamic processes, fostering speed and precision in drug analysis.

What sets it apart

DeepkinetiX stands out by leveraging patient-derived data for enhanced accuracy in predictive modeling, aiming to minimize animal testing and improve drug development outcomes.

Funding history

1 round
OptionsMar 3, 2025
Form D
+$1.0M$1.0M total

Latest SEC filings

via EDGAR · CIK 0002060288
Form D · Mar 3, 2025View on EDGAR

Products

1 tracked

KinetixFlow™

Software Platform

KinetixFlow™ is an advanced AI-powered software platform specifically designed for pharmacokinetic and pharmacodynamic analysis. It integrates complex algorithms to analyze extensive data sets, predicting how drugs will behave in the human body and significantly optimizing dosing strategies.

  • AI-driven predictive analytics
  • Real-time pharmacokinetic/pharmacodynamic modeling
  • Enhanced accuracy with patient-derived cellular data
  • Streamlined workflows for drug discovery and trial design

Links

WebsiteSEC EDGAR filings